Evaluation of the safety and efficacy of the novel Mycoplasma gallisepticum vaccine, Vaxsafe MG304, after spray-vaccination of 1-day-old specific pathogen-free chicks.

Autor: Kanci Condello A; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Parkville, Victoria 3010, Australia. Electronic address: anna.kancicondello@unimelb.edu.au., Wawegama NK; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Parkville, Victoria 3010, Australia., Ekanayake D; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Parkville, Victoria 3010, Australia., Zhu L; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Werribee, Victoria 3030, Australia., Tivendale KA; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Parkville, Victoria 3010, Australia., Shil PK; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Werribee, Victoria 3030, Australia., Daly J; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Werribee, Victoria 3030, Australia., Mohotti S; Bioproperties Proprietary Limited Research & Diagnostic Laboratory (RDL), RMIT University, Bundoora, Victoria 3083, Australia., Todhunter P; Bioproperties Proprietary Limited, 36 Charter Street, Ringwood, Victoria 3134, Australia., Underwood GJ; Bioproperties Proprietary Limited, 36 Charter Street, Ringwood, Victoria 3134, Australia., Noormohammadi AH; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Werribee, Victoria 3030, Australia., Markham PF; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Parkville, Victoria 3010, Australia., Browning GF; Asia-Pacific Centre for Animal Health, Melbourne Veterinary School, Faculty of Science, University of Melbourne, Parkville, Victoria 3010, Australia.
Jazyk: angličtina
Zdroj: Veterinary microbiology [Vet Microbiol] 2024 Jun; Vol. 293, pp. 110093. Date of Electronic Publication: 2024 Apr 14.
DOI: 10.1016/j.vetmic.2024.110093
Abstrakt: Mycoplasma gallisepticum causes chronic respiratory disease in poultry. A novel vaccine, Vaxsafe MG304 (the ts-304 strain), has greater protective efficacy in chickens than the Vaxsafe MG (strain ts-11) vaccine when delivered by eye drop at 3 weeks of age. Applying this vaccine in the hatchery to 1-day-old birds, using mass administration methods, would improve animal welfare and reduce labour costs associated with handling individual birds. This study assessed the protection provided by vaccination with Vaxsafe MG304 after administration to 1-day-old chicks. Chicks were administered a single dose of the vaccine to assess the efficacy of either a high dose (10 7.0 colour changing units, CCU) or a low dose (10 5.7 CCU) after eye drop or spray (in water or gel) administration against experimental challenge with virulent M. gallisepticum strain Ap3AS at 7 weeks of age. The vaccine was able to colonise the palatine cleft of chicks after vaccination by eye drop (at both doses) or by spray (in water or gel) (at the high dose). The high dose of vaccine, when delivered by eye drop or spray, was shown to be safe and induced a serological response and protective immunity (as measured by tracheal mucosal thickness and air sac lesion scores) against challenge. Vaccination of 1-day-old chicks with Vaxsafe MG304 by eye drop induced protective immunity equivalent to vaccination at 3 weeks of age. Vaxsafe MG304 was also protective when applied by both coarse- and gel spray methods at the higher dose and is therefore a suitable live attenuated vaccine for use in 1-day-old chicks.
Competing Interests: Declaration of Competing Interest Gregory J. Underwood, Philip Todhunter and Sameera Mohotti are employees of Bioproperties Pty. Ltd. The University of Melbourne licences the M. gallisepticum ts-11 and Vaxsafe MG304 vaccines to Bioproperties Pty. Ltd. and, as employees of the university involved in the creation of Vaxsafe MG304, A.KC, P.K.S, P.F.M and G.F.B are entitled to a share of any royalties generated from this license. The other authors have no potential conflicts of interest (financial, professional or personal) related to the research reported here.
(Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: